Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.
about
A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents.Social Media and Myeloproliferative Neoplasms (MPN)--Focus on Twitter and the Development of a Disease-specific Community: #MPNSM.Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors.Physical Activity as a Nonpharmacological Symptom Management Approach in Myeloproliferative Neoplasms: Recommendations for Future Research.Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.[New treatment options for chronic pruritus].
P2860
Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Reducing symptom burden in pat ...... ra of Janus kinase inhibitors.
@en
type
label
Reducing symptom burden in pat ...... ra of Janus kinase inhibitors.
@en
prefLabel
Reducing symptom burden in pat ...... ra of Janus kinase inhibitors.
@en
P2093
P2860
P1433
P1476
Reducing symptom burden in pat ...... ra of Janus kinase inhibitors.
@en
P2093
Holly L Geyer
Robyn M Scherber
Ruben A Mesa
P2860
P304
P356
10.3109/10428194.2014.983098
P577
2015-03-17T00:00:00Z